Study ties high-dose Wegovy to fivefold eye-stroke risk versus Ozempic
A study of FDA adverse-event reports (2017–2024) found Wegovy’s high-dose semaglutide for obesity linked to about five times the risk of non-arteritic anterior ischemic optic neuropathy (NAION) compared with Ozempic’s diabetes-dose semaglutide, with men at higher risk than women. Rybelsus and tirzepatide showed no increased risk. The findings are observational and do not prove causation; NAION is rare (roughly 1 in 10,000 on semaglutide). Regulators have issued warnings and Novo Nordisk says the overall benefit–risk profile remains favorable while continuing safety monitoring.